NCT00833664View on ClinicalTrials.gov

Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

January 31, 2002

Study Completion Date

January 31, 2002

Conditions
Healthy
Interventions
DRUG

Terbinafine HCl 250mg tablets

1 x 250 mg

DRUG

Lamisil® 250 mg Tablets

1 x 250 mg

Trial Locations (1)

15206-3817

Novum Pharmaceutical Research Services, Pittsburgh

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY

NCT00833664 - Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions | Biotech Hunter | Biotech Hunter